PRATIA SPAIN has announced a new joint venture in Spain with UOMi (Oncology unit of Clínicas Mi). The joint venture, named “PRATIA SIRIUS”, integrates the assets of UOMI as a clinical trial service provider in the Spanish market with the innovative investment and expertise of PRATIA SPAIN, offering a unique opportunity to Spanish doctors and patients.Dr. Santiago Vitera, Director of UOMI, stated: “This new journey with PRATIA SPAIN will expedite the cancer research process delivering faster and better results for patients in a breakthrough model in Spain”.Lukasz Bęczkowski, COO of PRATIA, commented: “Excited to bring dedicated research site model to Spain! Pratia continues to increase patients’ access to innovative therapies and strategic growth in oncology! Honoured to have you Santiago and your experienced team with us!”.Tomek Dabrowski, CFO of PRATIA, remarked: “As PRATIA spearheads a global consolidation of dedicated research centres with a special focus on oncology, establishing such a model in Spain —a country that ranks as the third largest in Clinical Research— is a pivotal move for us. Finding partners like Dr. Santiago and the entire teams at UAMi and Clinica Mi bolsters my confidence in successful collaboration and anticipates even larger growth in the Spanish research landscape. I am convinced that with a team like this, our journey will not only be productive but also enjoyable.”The official signing ceremony took place on Thursday, April 11, 2024.PRATIA SPAIN is an SMO with over 20 years of experience. Over the years, PRATIA SPAIN has adapted to the needs of patients and professionals in the sector. Currently, PRATIA SPAIN offers innovative treatments to our patients and a wide range of services related to clinical research to all our partners.UOMi is the Oncology Unit of Clínicas Mi, comprising Clínica Mi Tres Torres in Barcelona and Clínica Mi NovAliança in Lleida. The UOMi team is a highly specialized multidisciplinary unit dedicated to comprehensive care for oncology patients, led by oncologist Dr Santiago Viteri, from rapid and precise diagnosis to offering the most appropriate and effective treatment in each case and providing personalized and attentive support to patients and their families.With this agreement, PRATIA SPAIN and UOMi are committed to leading the SMO in the Spanish market and offering services to private and public healthcare entities.One of the principals, Alex Pascual, led the team from CASAMIQUELA & PASCUAL ADVISORS, to advise UOMi. Alex Pascual commented: “We are very proud and happy with the agreement. We believe it will be an opportunity to promote and improve the clinical trials sector in Spain, in a way that has never been done before”.PRATIA SPAIN was led by the Corporate and M&A team of Mariscal Abogados, namely Alberto Álvarez (partner) and Irene Terrazas (partner), along with associate Guillermo Contreras. Alberto Álvarez and Irene Terrazas commented: “We are very pleased with the business relationship between PRATIA SPAIN and UOMi during the negotiations. It has eased the path for their business to grow together in the coming years”.Mariscal Abogados specializes in medium-scale, award-winning and market-leading transactions in Spain & Portugal, providing sector-focused advice within the context of M&A transactions, focusing on asset-level due diligence and joint ventures, as well as regulatory and government agreements advice.
